ArticleHepatobiliary surgery and nutrition2025
The risk of hepatocellular carcinoma recurrence after liver transplantation increases with locoregional therapies in patients initially within Milan criteria.
Article in Hepatobiliary surgery and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal timing of transplantation for hepatocellular carcinoma (HCC) is still under debate regarding the tumor biology and locoregional control with various treatments. We designed this study to find out what kind of factors affect the post-transplantation outcome focusing on the timing of transplantation. Methods: We analyzed HCC patients who met the Milan criteria at the initial stage and subsequently underwent liver transplantation (LT) between 2007 and 2020. We examined the number of locoregional therapies (LRTs) received, as well as data on tumor recurrence and survival. The number of LRTs was categorized into four groups: none, one or two, three or four, and five or more. Both recurrence-free survival and overall survival were analyzed. Results: A total of 423 patients who met the Milan criteria at the initial stage underwent LT. The median number of LRTs before transplantation was 2, with an interquartile range of 0 to 4. There were 112 patients (26.5%) who underwent LT as the initial treatment. Multivariable Cox analyses showed that the number of LRTs [hazard ratio (HR) =1.219, 95% confidence interval (CI): 1.074-1.382, P=0.002] was a significant factor for recurrence. When analyzed as a categorical variable, three or four LRTs (HR =4.936, 95% CI: 1.790-13.615, P=0.002) and five or more LRTs (HR =5.129, 95% CI: 1.958-13.440, P=0.001) showed a significantly higher risk compared to the primary transplantation group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.